RecruitingPhase 1Phase 2NCT07081646

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment

91 participants

Start Date

Aug 18, 2025

Study Type

INTERVENTIONAL

Conditions

Amyloidosis Light Chain Amyloidosis Relapsed AL Amyloidosis Refractory AL Amyloidosis

Summary

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AZD0120 for people with amyloidosis, light chain amyloidosis, and other related conditions. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAZD0120

Participants will receive AZD0120 via intravenous (IV) infusion.

Locations(18)

Research Site

Phoenix, Arizona, United States

Research Site

San Francisco, California, United States

Research Site

Tampa, Florida, United States

Research Site

Boston, Massachusetts, United States

Research Site

Detroit, Michigan, United States

Research Site

Rochester, Minnesota, United States

Research Site

St Louis, Missouri, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

Cleveland, Ohio, United States

Research Site

Nashville, Tennessee, United States

Research Site

Calgary, Alberta, Canada

Research Site

Calgary, Alberta, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

London, United Kingdom

Research Site

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07081646

Related Trials

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT072246725 locations

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895103 locations

Dietary Reporting In The Amyloidoses

NCT057380051 location

Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis

NCT046366841 location

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT069748771 location